Qiagen stock gains after Q2 beat and fresh FDA clearance

Qiagen stock is trading around $43 after a Q2 beat and a new FDA clearance lifted attention to its diagnostics pipeline.

Qiagen N.V. (ISIN NL0012169213) stock was last quoted at $43.00 on August 13, 2026, after the company said second-quarter net sales were $535 million and adjusted diluted EPS reached $0.62. The share price sat near the session high of $43.07, with a market cap of $8.93 billion and volume of 3.12 million shares.

Q2 beat holds the spotlight

Management said the quarter exceeded its own outlook, with sales roughly flat year over year and adjusted EPS above the $0.60 target at constant exchange rates. The company also reaffirmed full-year guidance for sales growth of 1% to 2% at constant exchange rates and adjusted EPS of at least $2.43.

That mix matters because the guide implies a stronger second half, with Q3 sales also expected to rise 1% to 2% at constant exchange rates. Adjusted operating income in Q2 was $157 million, while the margin was 29.4%, down 50 basis points from 29.9% a year earlier.

Product launches add support

Qiagen said Sample Technologies sales rose 9% at constant exchange rates, QIAcuity delivered double-digit growth, and universal NGS consumables grew more than 20%. The company also said its second-half sales growth should improve to 3% to 4% at constant exchange rates, a jump of about 4 to 5 percentage points from the minus 1% first-half pace.

One lever is the diagnostics menu. Qiagen said its new QIAstat-Dx bloodstream infection panels detect 33 pathogens and 28 antimicrobial resistance markers in about 1 hour, and it expects U.S. FDA approval by the end of 2026.

Sample to Insight tools

Qiagen's Sample to Insight portfolio includes Sample Technologies, QIAcuity, QuantiFERON, and QIAstat-Dx, with the latest call also highlighting Parse and upcoming gene-expression assays. The company said operating cash flow was $301 million in the first half of 2026, while days sales outstanding improved to 55 days from 57 days at the end of 2025.

Qiagen stock holds firm

Qiagen stock traded at $43.00 on August 13, 2026, after reaching $43.07 intraday and $42.13 on the low end of the session. The 52-week range ran from $32.53 to $57.82, and the market's focus now sits on whether the second-half sales ramp reaches the company's 3% to 4% target.

Qiagen key figures

• Company: Qiagen N.V.
• ISIN: NL0012169213
• Ticker: QGEN
• Exchange: NYSE
• Price (as of August 13, 2026, 2:04 a.m. ET): $43.00 USD
• Market cap: $8.93 billion (as of August 13, 2026)
• Sector / Industry: Health Care, Diagnostics & Research
• Index membership: Nasdaq-100
• Next earnings date: not yet officially scheduled